MS
VRTX icon

Maven Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

Maven Securities’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,400
Closed -$966K – 995
2024
Q4 		$966K Buy
+2,400
New +$1.11M 0.02% 423
2024
Q1 		– Sell
-6,500
Closed -$2.64M – 988
2023
Q4 		$2.64M Buy
6,500
+5,600
+622% +$2.07M 0.05% 253
2023
Q3 		$313K Buy
+900
New +$315K ﹤0.01% 937

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Maven Securities's VRTX Position: Q1 2022 in Review

Maven Securities sold out of Vertex Pharmaceuticals (VRTX) in Q1 2022, closing a stake of 3,588 shares — an estimated $788K sold.

Maven Securities first reported a position in VRTX in Q4 2016 and held it in 7 quarters. The position peaked at $931K in Q1 2021. 1,073 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

  • Maven Securities reported no remaining Vertex Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Maven Securities sold 3,588 Vertex Pharmaceuticals shares in Q1 2022, an estimated $788K.
  • Maven Securities first reported a position in Vertex Pharmaceuticals in Q4 2016 and held it in 7 quarters.
  • Maven Securities's Vertex Pharmaceuticals position peaked at $931K in Q1 2021.
  • 1,073 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on Maven Securities's 13F filing for Q1 2022, filed 16 May 2022.